BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 125 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,771,897 | +11.5% | 2,368,912 | +10.8% | 0.04% | +13.2% |
| Q2 2023 | $15,048,788 | -18.1% | 2,137,612 | -3.0% | 0.04% | -19.1% |
| Q1 2023 | $18,370,618 | -18.8% | 2,202,712 | +11.8% | 0.05% | -25.4% |
| Q4 2022 | $22,626,070 | -10.9% | 1,970,912 | -2.2% | 0.06% | -14.9% |
| Q3 2022 | $25,399,000 | +15.2% | 2,015,812 | -3.2% | 0.07% | +17.5% |
| Q2 2022 | $22,042,000 | -23.5% | 2,083,412 | +17.6% | 0.06% | -18.2% |
| Q1 2022 | $28,797,000 | -3.4% | 1,771,012 | -17.7% | 0.08% | +2.7% |
| Q4 2021 | $29,804,000 | +8.0% | 2,151,912 | +12.0% | 0.08% | +4.2% |
| Q3 2021 | $27,605,000 | +146.6% | 1,921,012 | +171.3% | 0.07% | +140.0% |
| Q2 2021 | $11,195,000 | +391.0% | 708,112 | +215.8% | 0.03% | +400.0% |
| Q1 2021 | $2,280,000 | -76.6% | 224,212 | -82.9% | 0.01% | -76.9% |
| Q4 2020 | $9,757,000 | +50.3% | 1,309,712 | -30.7% | 0.03% | +36.8% |
| Q3 2020 | $6,490,000 | -35.7% | 1,889,312 | -10.8% | 0.02% | -36.7% |
| Q2 2020 | $10,096,000 | +215.5% | 2,118,812 | +32.4% | 0.03% | +150.0% |
| Q1 2020 | $3,200,000 | -38.2% | 1,599,912 | +6.5% | 0.01% | 0.0% |
| Q4 2019 | $5,181,000 | +106.7% | 1,501,812 | +71.7% | 0.01% | +100.0% |
| Q3 2019 | $2,507,000 | +50.5% | 874,912 | +99.0% | 0.01% | +50.0% |
| Q2 2019 | $1,666,000 | +5.6% | 439,612 | +126.8% | 0.00% | 0.0% |
| Q1 2019 | $1,578,000 | +18.2% | 193,812 | +17.2% | 0.00% | 0.0% |
| Q4 2018 | $1,335,000 | -11.7% | 165,412 | -16.5% | 0.00% | 0.0% |
| Q3 2018 | $1,512,000 | +55.9% | 198,212 | +17.1% | 0.00% | +33.3% |
| Q2 2018 | $970,000 | +117.0% | 169,212 | +80.4% | 0.00% | +200.0% |
| Q1 2018 | $447,000 | -3.7% | 93,800 | -0.6% | 0.00% | 0.0% |
| Q4 2017 | $464,000 | +3.6% | 94,400 | +10.4% | 0.00% | 0.0% |
| Q3 2017 | $448,000 | +26.9% | 85,500 | +34.6% | 0.00% | 0.0% |
| Q2 2017 | $353,000 | +38.4% | 63,512 | +108.8% | 0.00% | 0.0% |
| Q1 2017 | $255,000 | +13.8% | 30,412 | +32.7% | 0.00% | -50.0% |
| Q3 2014 | $224,000 | -70.5% | 22,912 | -61.6% | 0.00% | -66.7% |
| Q2 2014 | $760,000 | – | 59,612 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |